Profile data is unavailable for this security.
About the company
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
- Revenue in USD (TTM)2.38bn
- Net income in USD770.95m
- Incorporated2020
- Employees100.00
- LocationRoyalty Pharma PLC110 East 59th StreetNEW YORK 10022United StatesUSA
- Phone+1 (212) 883-0200
- Websitehttps://www.royaltypharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | 353.78m | -797.12m | 14.50bn | 725.00 | -- | -- | -- | 40.99 | -4.19 | -4.19 | 1.86 | -10.03 | 0.4254 | -- | -- | 487,972.40 | -96.88 | -75.74 | -125.35 | -94.24 | 95.78 | 96.67 | -227.74 | -716.92 | 3.76 | -2.89 | 3.52 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
| Moderna Inc | 1.94bn | -2.82bn | 16.50bn | 5.80k | -- | 1.91 | -- | 8.49 | -7.26 | -7.26 | 5.00 | 22.14 | 0.1468 | 5.34 | 7.17 | -- | -21.31 | 10.19 | -25.32 | 13.43 | 62.91 | 75.16 | -145.16 | 19.02 | 3.22 | -- | 0.0659 | -- | -39.93 | 19.33 | 20.75 | -- | 24.53 | -- |
| Viatris Inc | 14.12bn | -3.69bn | 18.16bn | 32.00k | -- | 1.20 | -- | 1.29 | -3.10 | -3.10 | 11.96 | 13.13 | 0.3417 | 2.09 | 4.90 | 441,387.50 | -8.93 | -0.1756 | -10.89 | -0.2096 | 39.36 | 40.66 | -26.13 | -0.5768 | 0.793 | 2.79 | 0.4868 | -- | -4.46 | 5.09 | -1,259.42 | -- | -3.10 | -- |
| Roivant Sciences Ltd | 13.31m | -809.24m | 18.93bn | 750.00 | -- | 4.40 | -- | 1,422.26 | -1.17 | -1.17 | 0.0193 | 6.02 | 0.0024 | -- | -- | 17,746.67 | -18.26 | 5.89 | -20.80 | 6.98 | 91.21 | 90.39 | -7,558.42 | 639.97 | -- | -- | 0.00 | 0.00 | -11.19 | -15.56 | -111.69 | -- | -1.32 | -- |
| Incyte Corp | 5.14bn | 1.29bn | 20.12bn | 2.84k | 15.79 | 3.88 | 14.58 | 3.91 | 6.40 | 6.40 | 25.61 | 26.04 | 0.8291 | 4.33 | 5.48 | 1,807,750.00 | 20.75 | 11.34 | 27.83 | 14.38 | 93.26 | 93.92 | 25.03 | 16.48 | 3.25 | -- | 0.0067 | 0.00 | 21.22 | 14.03 | 3,844.96 | -- | -20.67 | -- |
| United Therapeutics Corp | 3.13bn | 1.27bn | 20.39bn | 1.31k | 17.93 | 3.08 | 15.06 | 6.52 | 26.41 | 26.41 | 64.94 | 153.61 | 0.4323 | 2.21 | 9.78 | 2,397,242.00 | 17.57 | 13.61 | 19.48 | 14.84 | 88.59 | 90.79 | 40.65 | 37.81 | 6.07 | -- | 0.00 | 0.00 | 23.63 | 14.71 | 21.35 | -- | 24.11 | -- |
| Royalty Pharma plc | 2.38bn | 770.95m | 26.07bn | 100.00 | 25.38 | 4.03 | 29.14 | 10.96 | 1.78 | 1.78 | 4.21 | 11.22 | 0.1257 | -- | 84.52 | 23,781,930.00 | 7.00 | 6.72 | 9.03 | 9.10 | -- | -- | 55.68 | 50.56 | -- | 7.06 | 0.4795 | 50.52 | 5.06 | 2.30 | -10.25 | 9.26 | -4.90 | 24.01 |
| Biogen Inc | 9.89bn | 1.29bn | 28.84bn | 7.50k | 22.32 | 1.58 | 13.91 | 2.92 | 8.81 | 8.81 | 67.37 | 124.45 | 0.3441 | 1.04 | 5.30 | 1,318,747.00 | 4.50 | 6.70 | 5.32 | 7.93 | 75.69 | 78.49 | 13.07 | 17.28 | 2.03 | 5.74 | 0.2562 | 0.00 | 2.22 | -5.96 | -20.79 | -20.22 | -19.60 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley Investment Management, Inc.as of 31 Dec 2025 | 37.30m | 8.73% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2025 | 31.10m | 7.28% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 17.79m | 4.17% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 17.08m | 4.00% |
| Baillie Gifford & Co.as of 31 Dec 2025 | 17.01m | 3.98% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 12.87m | 3.01% |
| Adage Capital Management LPas of 30 Sep 2025 | 11.97m | 2.80% |
| Swedbank Robur Fonder ABas of 31 Dec 2025 | 11.94m | 2.80% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 10.65m | 2.49% |
| Geode Capital Management LLCas of 31 Dec 2025 | 7.72m | 1.81% |
